Two Sigma Advisers LP raised its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 72.1% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 800,800 shares of the company's stock after acquiring an additional 335,400 shares during the quarter. Two Sigma Advisers LP owned approximately 1.13% of Ventyx Biosciences worth $1,754,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently bought and sold shares of the business. Bank of America Corp DE grew its position in Ventyx Biosciences by 376.4% in the 4th quarter. Bank of America Corp DE now owns 4,273,442 shares of the company's stock valued at $9,359,000 after acquiring an additional 3,376,446 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Ventyx Biosciences in the 4th quarter valued at $3,903,000. Geode Capital Management LLC grew its position in Ventyx Biosciences by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company's stock valued at $3,095,000 after acquiring an additional 21,337 shares during the last quarter. Millennium Management LLC grew its position in Ventyx Biosciences by 369.7% in the 4th quarter. Millennium Management LLC now owns 1,281,629 shares of the company's stock valued at $2,807,000 after acquiring an additional 1,008,760 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Ventyx Biosciences by 88.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock valued at $1,909,000 after acquiring an additional 409,357 shares during the last quarter. Institutional investors own 97.88% of the company's stock.
Ventyx Biosciences Stock Performance
Ventyx Biosciences stock traded down $0.05 during mid-day trading on Tuesday, hitting $1.99. The company's stock had a trading volume of 1,624,178 shares, compared to its average volume of 1,360,042. The company has a 50 day moving average of $1.28 and a 200-day moving average of $1.72. The stock has a market cap of $141.61 million, a PE ratio of -0.84 and a beta of 0.73. Ventyx Biosciences, Inc. has a one year low of $0.78 and a one year high of $5.66.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. On average, equities research analysts forecast that Ventyx Biosciences, Inc. will post -2.09 EPS for the current fiscal year.
About Ventyx Biosciences
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Featured Articles
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
